menu
    • menu
    [{"orgOrder":0,"company":"RDC Clinical","sponsor":"Gencor Pacific Limited","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Oleoylethanolamide","moa":"Peroxisome proliferator-activated receptor alpha; G-protein coupled receptor 55; Glucose-dependent insulinotropic receptor; Cannabinoid receptor 1","graph1":"Undisclosed","graph2":"Phase IV","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RDC Clinical \/ Gencor Pacific Limited","highestDevelopmentStatusID":"11","companyTruncated":"RDC Clinical \/ Gencor Pacific Limited"},{"orgOrder":0,"company":"doTERRA International","sponsor":"Nicole Stevens, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Oleoylethanolamide","moa":"Peroxisome proliferator-activated receptor alpha; G-protein coupled receptor 55; Glucose-dependent insulinotropic receptor; Cannabinoid receptor 1","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"doTERRA International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"doTERRA International \/ Nicole Stevens, PhD","highestDevelopmentStatusID":"1","companyTruncated":"doTERRA International \/ Nicole Stevens, PhD"}]

    Find Clinical Drug Pipeline Developments & Deals for Oleoylethanolamide

    Menu

    Oleoylethanolamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            doTERRA International

                            Country arrow
                            Global ChemShow
                            Not Confirmed

                            doTERRA International

                            Country arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oleoylethanolamide

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Nicole Stevens, PhD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Metabolic and Epigenetic Impact of FAAH Inhibitors and OEA

                            Details : Oleoylethanolamide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 17, 2025

                            Lead Product(s) : Oleoylethanolamide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Nicole Stevens, PhD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RDC Clinical

                            Australia arrow
                            Global ChemShow
                            Not Confirmed

                            RDC Clinical

                            Australia arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oleoylethanolamide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Gencor Pacific Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OEA and LipiSperse Metabolic Study

                            Details : Oleoylethanolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 21, 2025

                            Lead Product(s) : Oleoylethanolamide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Gencor Pacific Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth